In the ever-evolving cell therapy landscape, the challenge of potency assay development remains critical. At the 4th Cell Therapy Potency Assay Summit, we will unite analytical development ...

Not developing potency assays and gaining knowledge about MOAs early in the drug development process not only can break ATMP ...

A study in mice offers evidence that inhibiting EZH2 can enhance lymphoma immunogenicity and overcome CAR-T cell therapy resistance.

An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies.

In a new episode of the pharmaphorum podcast, web editor Nicole Raleigh discusses stem cell therapy, and accessibility to and affordability of such treatment, with Rafael E Carazo Salas ...

An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, ...

Stem cells in the intestine can adjust their function by using PIEZO channels that sense extracellular forces and activate ...

The non-cryopreserved CD19- and CD20-directed CAR T-cell therapy zamto-cel is manufactured in a closed-system device that ...

ESO-T01 is the first in vivo BCMA CAR-T candidate to reach the clinical stageEarly clinical data are expected in second half of ...

Explore how 'Conan' the bacterium resists extreme radiation, paving the way for breakthroughs in healthcare and space ...

GMP cell-based potency assays play an essential role in quantitatively measuring the biological activity of a biopharmaceutical, and the cytotoxicity of the payload of an Antibody-drug conjugate ...